The MJGT_F_H can ameliorate metabolic disorders in T2DM rats, and its mechanism of action primarily involves the following aspects: first, by upregulating the expression of p-AMPK in liver tissue, it activates the AMPK signaling pathway, thereby downregulating the expression of key gluconeogenic enzymes G6Pase and PEPCK. Here, G6PC1 is linked to metabolic disease.